Living With HIV: Long-term Care and U=U

This article is educational content based on current peer-reviewed guidelines, including the DHHS Adult and Adolescent ART Guidelines 2024, the IAS-USA 2024 Recommendations, and HIVMA/IDSA 2024 Primary Care Guidance. It is not personalised medical advice. HIV management decisions depend on individual circumstances and must be made in consultation with a healthcare provider.

Ready to discuss HIV care in George? Book a consultation with Dr Chellan.

What ART does and why it works so well now

Antiretroviral therapy (ART) is the combination of medications that stops HIV from replicating. It does not cure HIV. What it does, and does thoroughly, is reduce the amount of virus in the blood and tissues to levels so low that:

1. The virus cannot damage the immune system further.
2. The immune system recovers.
3. The virus cannot be transmitted to sexual partners.
4. The person can expect near-normal life expectancy.

Modern ART is a different medication to what was available 20 years ago, or even 10. The current generation of integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, offer three advantages that previous regimens did not combine:

• Faster viral suppression. Most people reach undetectable viral load within 8 to 12 weeks, versus 24 weeks or longer with older regimens.
• Higher barrier to resistance. Occasional missed doses do not readily generate drug resistance the way older regimens did.
• Better tolerability. Side effects are fewer and milder, and daily single-tablet regimens mean no separate pill schedules to track.

The practical result: HIV in 2026 is more like managing hypertension or type 2 diabetes than managing a terminal illness. It requires one daily tablet, regular blood tests every six months, and routine primary care attention to the rest of the body.

First-line ART in 2026: what you actually take

Current SAHCS and NDoH ART guidance, along with international recommendations, converges on integrase inhibitor based regimens as first-line therapy.

The most widely prescribed combinations:

• Tenofovir + lamivudine + dolutegravir (TLD), taken as a single fixed-dose tablet once daily. This is the South African public-sector first-line regimen and has been since 2019. It is highly effective, well tolerated, and available through medical aid schemes in the private sector as well.

• Bictegravir + tenofovir alafenamide + emtricitabine, also a single fixed-dose tablet once daily. More widely used in the private sector. Similar efficacy and tolerability to TLD, with a slightly different side-effect profile (more weight gain, less bone mineral density loss).

• Dolutegravir + lamivudine, a two-drug single-tablet regimen for people with viral load under 500,000 copies per mL and no hepatitis B coinfection. Not used in pregnancy.

What is no longer preferred:

Older regimens based on efavirenz, rilpivirine, raltegravir, or boosted protease inhibitors are not recommended as initial therapy in current guidelines. People who are doing well on older regimens are often switched to modern single-tablet regimens when appropriate, but this is a decision made with their clinician based on the specific situation.

Why combination therapy:

Every approved ART regimen contains two or more different antiretroviral drugs. This is because a single drug would quickly select for resistant virus. Combinations provide robust suppression and prevent resistance from emerging.

U=U: Undetectable equals Untransmittable

U=U stands for Undetectable equals Untransmittable. If you take your antiretroviral medication as prescribed and maintain a sustained undetectable viral load on ART, you cannot sexually transmit HIV to your partner. Not "low risk". Not "very unlikely". Zero.

This is one of the most consequential findings in HIV medicine, backed by the largest prospective transmission studies ever conducted (summarised in detail in the section below). U=U is not controversial. It is how HIV transmission biology actually works.

Every major HIV organisation in the world has endorsed U=U, including the CDC, WHO, IAS-USA, UNAIDS, the British HIV Association, and the Southern African HIV Clinicians Society. The Prevention Access Campaign's U=U consensus statement has been signed by over 1,100 organisations across 105 countries.

What undetectable actually means

A viral load test measures how many copies of HIV RNA are in a millilitre of blood. The threshold at which HIV cannot be transmitted sexually is less than 200 copies per mL.

The distinction matters:

• "Undetectable" means the viral load is below what the lab assay can measure. Most modern assays detect down to 50 copies per mL, and some down to 20 copies per mL.
• "Suppressed" is defined clinically as viral load under 200 copies per mL.

Both the CDC and IAS-USA define U=U based on the 200 copies per mL threshold. This reflects the actual evidence: the transmission studies involved people whose viral loads were all under 200, and no transmissions occurred. It also provides reassurance that an occasional "blip" below 200 copies per mL, which happens to many people on ART without clinical significance, does not compromise U=U protection.

How long does it take to become undetectable

For most people, viral load drops rapidly in the first 4 weeks of ART, reaches undetectable within 8 to 12 weeks, and stays there indefinitely as long as medication is taken. Some people take longer (particularly those starting with a very high baseline viral load over 500,000 copies per mL), but most reach undetectable within 6 months.

The typical timeline:

• 4 to 6 weeks in: a significant drop in viral load is expected. This is when the first check-in visit happens. Tolerability and any side effects are assessed.
• 8 to 12 weeks in: most adherent patients achieve full suppression. A viral load at 3 months should be undetectable or nearly so.
• Up to 24 weeks: a minority of people (particularly those with very high baseline viral loads) take longer.

A few practical points on relying on U=U:

• You are not protective to partners while viral load is still dropping. U=U applies only after viral load is confirmed undetectable on a blood test.
• Stay undetectable for at least 6 months before relying on U=U for transmission prevention. Current guidelines specifically recommend sustained suppression, meaning multiple undetectable results over that window. Use condoms or partner PrEP during the first 6 months.
• If your viral load becomes detectable again (a blip above 200 copies per mL), talk to your clinician. Brief spikes are common and often not meaningful; sustained detectability is a signal that needs investigation.

The clinical evidence for U=U in detail

Four major prospective studies, conducted over more than a decade across multiple continents, form the scientific foundation of U=U.

HPTN 052 (2011 to 2016): 1,763 serodifferent couples (one partner with HIV, one without) followed for a median 5.5 years. Couples were randomised to early vs deferred ART for the partner with HIV. The 2016 final analysis: zero phylogenetically linked HIV transmissions occurred when the partner with HIV was on ART with viral load suppression.

PARTNER 1 and PARTNER 2 (Europe, 2010 to 2018): 888 couples in PARTNER 1 (548 heterosexual, 340 gay male) and 972 gay male couples in PARTNER 2. Over the full study, couples reported 76,088 acts of condomless anal sex among gay couples alone. Zero phylogenetically linked transmissions occurred, despite 15 new HIV infections that were all traced to partners outside the study relationships. See Rodger et al., Lancet 2019 for the PARTNER2 final analysis.

Opposites Attract (Australia, Thailand, Brazil): Male-male serodifferent couples followed prospectively. Combined with PARTNER, these studies recorded 144,631 episodes of condomless vaginal or anal sex while the partner with HIV was virally suppressed. Zero linked transmissions.

The PARTNER study authors explicitly stated in their 2019 Lancet paper: *"The results from the PARTNER studies support wider dissemination of the message of the U=U campaign that risk of transmission of HIV in the context of virally suppressive ART is zero."*

The upper 95% confidence interval for transmission in PARTNER 2 was 0.23 per 100 couple-years. That is a ceiling so low that statisticians describe the actual risk as effectively zero. To put that in perspective: every other commonly cited "low-risk" HIV scenario (insertive oral sex without ejaculation, for example) has an actual documented transmission risk higher than this ceiling.

What U=U does NOT mean

U=U is a statement about HIV transmission specifically. It does not apply to several related questions that matter for people's lives:

• U=U does not protect against other STIs. Condoms still matter for preventing gonorrhoea, chlamydia, syphilis, herpes, and HPV. Annual STI screening is part of routine HIV care.
• U=U does not prevent pregnancy. Contraception is a separate decision.
• U=U has not been proven for injection drug use transmission. No direct studies have shown that viral suppression prevents transmission through shared injection equipment. It is plausible, but not proven. People who inject drugs should use sterile equipment regardless of viral status.
• U=U does not apply once viral load is detectable. If viral load rises above 200 copies per mL, transmission risk returns. This is why sustained adherence and regular viral load monitoring are essential.
• U=U applies to sexual transmission and (with caveats below) to pregnancy and birth, but is less clear-cut for breastfeeding.

U=U and pregnancy, birth, and breastfeeding

Pregnancy and birth (perinatal transmission):

A 2025 systematic review and meta-analysis in the Lancet, covering roughly 80,000 mother-child pairs, found zero perinatal HIV transmissions among women who started ART before pregnancy and maintained viral load under 50 copies per mL throughout. This is the strongest evidence yet that U=U applies to perinatal transmission when ART is established preconception and sustained.

The transmission risk rises sharply with higher viral loads:

• Viral load under 50 copies per mL: effectively 0%
• Viral load 50 to 999 copies per mL: around 1.3%
• Viral load 1,000 copies per mL or more: around 5.1%

For women diagnosed during pregnancy, the priority is rapid ART initiation and achieving suppression by delivery, which dramatically reduces transmission risk.

Breastfeeding:

This is where U=U becomes less clear-cut. Recent data suggest the monthly postnatal transmission risk with viral load under 50 copies per mL is very low but not zero. Rare transmissions have occurred even when maternal viral load was undetectable. Studies have been limited by infrequent viral load monitoring and older ART regimens.

Current SA and international guidance for women with HIV who choose to breastfeed:

• Maintain excellent ART adherence throughout breastfeeding
• Monitor viral load every 1 to 2 months
• Provide infant antiretroviral prophylaxis
• If viral load becomes detectable (especially 200 copies per mL or more), switch to formula feeding
• Exclusive breastfeeding for 6 months, then introduce complementary foods with gradual weaning

The decision to breastfeed vs formula feed involves weighing the small but real residual transmission risk against the substantial benefits of breastfeeding (nutrition, bonding, reduced infant infections). It is an individualised conversation. See our full article on HIV in pregnancy for detail.

Adherence: how strict is strict

Adherence is the most important variable in HIV treatment. Not dosing time precision. Not dietary restrictions. Just: do you take your tablet every day?

The good news is that modern single-tablet regimens tolerate imperfection better than older three-pill combinations did. A few missed doses per year will not derail treatment. What matters is the pattern: regular, daily, long-term.

A practical threshold: over 95% adherence (missing no more than two doses per month) is the target for durable viral suppression and reliable U=U. Below that, resistance risk climbs.

What the data show:

For integrase inhibitor regimens (TLD, bictegravir-based):

• 90% viral suppression is achieved at adherence levels as low as 75%
• Dolutegravir-based regimens show no significant difference in viral suppression across adherence levels from 80 to 100%
• Occasional missed doses (say, one per week) do not typically cause rebound

For older regimens (for comparison):

• Boosted protease inhibitors: 96% adherence was needed for 90% suppression
• NNRTI-based regimens: 78 to 98% adherence was needed

The practical takeaway:

Modern ART is more forgiving than the "99% adherence or catastrophe" messaging of the early 2000s. However, the goal is still consistent daily dosing, because:

• Sustained suppression is required for U=U
• Inconsistent adherence is linked to increased cardiovascular disease and mortality even when viral load remains suppressed
• Drug resistance, though less common with modern regimens, can still develop with prolonged interruptions

Strategies that help adherence:

• Link the dose to a daily anchor (morning coffee, brushing teeth at bedtime)
• Use a phone reminder or pill organiser
• Keep a small supply at work or in a travel bag for days when routine is disrupted
• Address the underlying barriers (transport, cost, stigma, mental health, substance use) rather than blaming yourself for missed doses
• Talk to Dr Chellan early if something is making adherence difficult; regimens can be switched or adjusted

What happens if you miss doses or stop

Time to viral rebound after stopping ART:

• Median time to viral load rising above 50 copies per mL: 16 days
• Median time to viral load above 400 copies per mL: 21 days
• Median time to viral load above 10,000 copies per mL: 32 days

Within a few months of stopping ART entirely, approximately 90% of people experience full viral rebound. This is why stopping ART, without replacing it with a different regimen, is not an option for people with HIV.

What to do if you miss a single dose:

Take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose. Do not double up. Get back onto the normal schedule and continue.

What to do if you miss doses repeatedly:

Contact the practice. A missed week or two is not a catastrophe with modern regimens, but it does need review. A viral load test may be needed to confirm suppression is intact. If not, the options include intensified adherence support or, rarely, a change of regimen.

When U=U protection ends:

If your viral load rises above 200 copies per mL, transmission risk returns. Additional prevention methods (condoms, PrEP for the partner) should be used until resuppression is confirmed by a repeat viral load test.

Routine monitoring once you are on ART

Once you are established on ART with a suppressed viral load, follow-up is relatively light.

Viral load:

• Every 3 to 4 months in the first year after starting ART
• Every 6 months once stable suppression is confirmed (at least 2 years of sustained suppression)
• More frequently if adherence concerns, new regimen, or suspected failure

CD4 count:

• Every 3 to 6 months for the first 2 years after starting
• Annually if CD4 is 300 to 500 cells per mm³ and virally suppressed for 2 years
• Optional if CD4 is above 500 and virally suppressed for over 2 years

Once you are virally suppressed and your CD4 is comfortably above 500, CD4 becomes less useful as a routine monitoring test. Viral load is the primary marker of treatment success.

Annual general health screening:

• Blood pressure and weight at every visit
• Lipid profile (cholesterol)
• Glucose or HbA1c for diabetes screening
• Kidney function (creatinine, eGFR)
• Liver enzymes
• Urinalysis if kidney disease risk factors
• STI screening (syphilis serology, gonorrhoea and chlamydia NAAT)
• Cervical cancer screening (Pap smear) annually for women, as an exception to the general population screening guidelines
• Bone density scan (DEXA) for postmenopausal women and men 50 or older
• Depression and anxiety screening using validated tools

Long-term health: cardiovascular risk and the REPRIEVE trial

Cardiovascular disease is now one of the principal causes of death in older people with HIV, exceeding AIDS-related causes in people who are virally suppressed. This is driven by a combination of traditional risk factors (smoking, hypertension, dyslipidaemia), HIV-associated chronic inflammation that is not completely switched off by ART, and, in some cases, metabolic effects of specific antiretroviral drugs.

The REPRIEVE trial (2024):

This practice-changing trial (Grinspoon et al., NEJM 2023) enrolled 7,769 people with HIV aged 40 to 75 years at low-to-moderate cardiovascular risk. Participants were randomised to a moderate-intensity statin (pitavastatin 4 mg daily) or placebo.

Results: major cardiovascular events reduced by 36% in the statin group (hazard ratio 0.64; 95% CI 0.48 to 0.84). The benefit was seen across demographics, CD4 counts, and viral load levels.

Current IAS-USA 2024 guidance based on REPRIEVE:

• Everyone with HIV aged 40 to 75 years with a 10-year ASCVD risk of 5% or higher: moderate to high intensity statin is recommended.
• Everyone with HIV aged 40 to 75 years with 10-year ASCVD risk under 5%: moderate intensity statin is suggested (pitavastatin 4 mg or equivalent).

In practical terms: if you are over 40 and living with HIV, a conversation about starting a statin is part of standard care, even if your cholesterol is not dramatically elevated. This is genuinely new guidance in 2024/25, and it is part of what Dr Chellan discusses at routine HIV reviews.

Other cardiovascular care:

• Blood pressure managed to under 130/80 mmHg where tolerated
• Smoking cessation (the single highest-yield cardiovascular intervention in HIV)
• Weight and metabolic health management
• Diabetes screening annually, with treatment if diagnosed

A word on integrase inhibitors and weight:

Modern integrase inhibitors (dolutegravir, bictegravir) are associated with modest weight gain, particularly in the first 1 to 2 years after starting or switching. Observational data also suggest a small signal for new-onset diabetes, partly but not entirely explained by weight gain. Women and people of African descent appear to gain slightly more weight on average than men or other demographic groups. The clinical response is not to abandon integrase inhibitors (they are the most effective, best-tolerated, highest-barrier-to-resistance drugs available) but to build weight, waist circumference, blood pressure, and glucose into routine HIV follow-up. That is now standard of care, and it is part of what Dr Chellan reviews at every visit.

Long-term health: bones, kidneys, liver, and cancer screening

Bones:

People with HIV have moderately reduced bone mineral density compared to the general population, driven partly by HIV itself and partly by certain ART regimens (particularly older tenofovir disoproxil fumarate). A baseline DEXA scan is recommended for postmenopausal women and men aged 50 or older, and repeated if risk factors are present.

Kidneys:

Kidney function is tracked through creatinine and eGFR at least annually. Tenofovir disoproxil fumarate can occasionally cause kidney issues, which is why monitoring is built into routine ART care. Tenofovir alafenamide, the newer version, has a better kidney safety profile.

Liver:

Liver enzymes are monitored periodically. Hepatitis B and C are screened for at diagnosis and managed if present (hepatitis B is often treated with the same tenofovir in the ART regimen). For people with cirrhosis or significant fibrosis, liver ultrasound plus AFP every 6 months screens for hepatocellular carcinoma.

Cancer screening:

People with HIV have higher rates of certain cancers, even with well-controlled HIV:

• Cervical cancer: annual Pap smear (with or without HPV co-testing), lifelong. This is more intensive than the general SA population screening schedule.
• Anal cancer: for men who have sex with men and transgender women over 35, and others over 45, annual digital rectal exam plus anal cytology is recommended where available.
• General cancer screening: as per SA population guidelines for lung, colon, breast, and prostate cancer.
• HPV vaccination: recommended up to age 45 where available and affordable.

Mental health and HIV

Living with HIV is not only a medical condition. The diagnosis itself, the adjustment, disclosure decisions, stigma, relationship dynamics, and the long view of lifelong medication all carry mental weight.

Depression is roughly twice as common in people with HIV as in the general population. Anxiety, adjustment disorders, and substance use are all elevated. This is not a moral failing or a sign of weak coping. It is a recognised clinical pattern that deserves active treatment.

At NeoHealth, mental health is a core part of HIV consultation, not an afterthought. Screening at diagnosis, again at 3 months, and then annually or as needed. Referral to psychology, psychiatry, or medication initiation where indicated.

Screening tools:

Validated instruments used in routine HIV care include the PHQ-9 for depression and GAD-7 for anxiety. Additional screening for substance use and trauma symptoms happens where clinically relevant.

Management:

• Psychotherapy (CBT has good evidence in HIV-associated depression)
• Antidepressants where indicated (with attention to drug interactions with ART; most modern antidepressants are compatible, some require dose adjustments)
• Peer support and community connection
• Addressing social determinants where possible

Dr Chellan, co-founder of NeoHealth, holds an FPD Certification in Clinical Management of Mental Health. Where antidepressant treatment or integrated mental health management is part of HIV care, this is handled within the practice, with referral to psychology or psychiatry when indicated.

Cognitive changes:

A proportion of people with HIV experience mild cognitive changes, particularly with longer duration of infection or a history of low CD4 nadir. Most are subtle. Management includes optimising ART, treating comorbidities (cardiovascular disease, sleep issues), and addressing substance use where relevant.

Drug interactions that matter

ART is generally well behaved with most common medications, but a few interactions are worth specific attention.

Tuberculosis treatment (rifampicin):

Rifampicin induces liver enzymes and reduces the levels of several antiretrovirals. With TLD (tenofovir + lamivudine + dolutegravir), the workaround is straightforward: dolutegravir is increased from 50 mg once daily to 50 mg twice daily while on rifampicin, returning to once daily two weeks after finishing TB treatment. This is routine and well established in SA primary care.

Some newer regimens (bictegravir-based, long-acting cabotegravir, lenacapavir) are not compatible with rifampicin and require switching during TB treatment. Dr Chellan can advise on the specific situation.

Contraceptives:

Rifampicin (during TB treatment) reduces the effectiveness of oral contraceptives. A barrier method or non-oral contraceptive (IUD, injection, implant) is recommended during TB treatment and for a month after. Dolutegravir and bictegravir themselves do not significantly interact with hormonal contraceptives.

Antacids and supplements:

Integrase inhibitors (dolutegravir, bictegravir) bind to multivalent cations (calcium, magnesium, iron, zinc). Antacids, calcium supplements, and iron tablets should be taken at least 2 hours before or 6 hours after the ART tablet. This is easy to manage once you know it.

Anticonvulsants:

Older enzyme-inducing anticonvulsants (phenytoin, phenobarbital, carbamazepine) reduce ART levels. Newer alternatives (levetiracetam, valproate) are preferred for people on ART.

Statins:

Most modern statins (atorvastatin, rosuvastatin, pitavastatin) are compatible with ART, though dose adjustments may apply. Simvastatin and lovastatin should be avoided with boosted protease inhibitors.

The routine practice at a PrEP/HIV review is to check every new medication against the ART regimen. If you are starting something new, mention your HIV medications to the prescriber, and mention any new medication at your next HIV review.

Planning a pregnancy when you or your partner has HIV

This is where U=U has transformed what was once a fraught and medically complex conversation.

If the partner with HIV is virally suppressed:

HPTN 052 and the PARTNER studies included serodifferent couples who were conceiving naturally through timed intercourse. Zero sexual transmissions occurred. A prospective cohort of 161 serodifferent couples conceiving naturally reported 144 pregnancies with zero sexual or vertical transmissions when the partner with HIV was virally suppressed.

The practical implication: for most serodifferent couples in 2026, natural conception through timed intercourse is both safe and the recommended approach when the partner with HIV is on ART and virally suppressed, and there are no fertility issues.

Additional layers of reassurance some couples choose:

• PrEP for the HIV-negative partner during conception attempts. Not necessary if U=U status is confirmed, but some couples prefer the additional peace of mind.
• More frequent viral load monitoring for the partner with HIV during the conception period.

For women with HIV planning pregnancy:

• Aim to be virally suppressed for at least 6 months before conception.
• Confirm the ART regimen is pregnancy-compatible. TLD and bictegravir-based single-tablet regimens are considered first-line in pregnancy. Some two-drug regimens (DTG/3TC, DTG/rilpivirine) and long-acting injectables are not recommended in pregnancy and would be switched before or on pregnancy diagnosis.
• Optimise overall health: folic acid, hepatitis B status, screening and treatment for STIs, blood pressure, weight, mental health.
• Antenatal viral load monitoring is more frequent than standard (typically monthly).

See our HIV in pregnancy article for detail.

For HIV care at NeoHealth, including ART initiation, long-term monitoring, U=U consultation, and pregnancy planning, book a consultation with Dr Chellan. First-time HIV diagnosis consultations are unhurried and confidential. Within our general practice, Dr Chellan offers full-spectrum HIV care, drawing on the Diploma in HIV Management (CMSA).

For related topics, see HIV testing, PrEP (HIV prevention), and PEP (post-exposure prophylaxis). For urgent PEP enquiries (a possible HIV exposure in the last 72 hours), call the practice immediately.

For Discovery Health members, the HIV Care Programme formalises this long-term continuity, with viral load and CD4 monitoring, regimen switching when needed, and integrated care for any other conditions you live with. Both Dr Chellan and Dr Lakay are accredited Premier Plus HIV GPs.

Important: This article provides general information on long-term HIV management and U=U based on current peer-reviewed guidelines, including the DHHS 2024 Adult and Adolescent ART Guidelines, IAS-USA 2024 Recommendations, HIVMA/IDSA 2024 Primary Care Guidance, and the PARTNER, HPTN 052, and Opposites Attract studies. It is intended for educational purposes only. It is not personalised medical advice. Every situation is different. Please seek the advice of Dr Chellan or another qualified healthcare provider for any individual HIV care questions.

Sources and references

• SAHCS Adult ART Guidelines. SAHCS guidelines for antiretroviral therapy in adults. Southern African HIV Clinicians Society.
• NDoH Knowledge Hub. ART Clinical Guidelines for adults, adolescents, children, and infants. South African National Department of Health.
• Rodger AJ et al. PARTNER2. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy. Lancet 2019 (PubMed).
• Cohen MS et al. HPTN 052. Antiretroviral therapy for the prevention of HIV-1 transmission. NEJM 2016 (PubMed).
• Grinspoon SK et al. REPRIEVE. Pitavastatin to prevent cardiovascular disease in HIV infection. NEJM 2023 (PubMed).
• World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. WHO.
• IAS-USA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, 2024 Recommendations. International Antiviral Society, USA Panel.

Content on this page is based on these sources and current clinical practice at NeoHealth. It is general health information, not personalised medical advice. Book a consultation for individual assessment.